Focus: Chronic Myeloid Leukaemia

Today, life expectancy is on a par with the general population, but the real challenge now lies in early treatment, tolerability and freedom from medication

Profile, diagnosis and treatment prospects for a disease that is no longer fatal but chronic

Treatments have revolutionised the natural history of the disease. Here’s how it is managed and why research must continue

From research to personalised treatments: this is how we manage the condition today

It is no longer enough simply to ask whether a medicine works or not; we need to understand what it is like to take it every day, often for an indefinite period, and sometimes for the rest of one’s life

Patients’ unmet needs beyond the success of treatment

The account of someone who has lived with the condition for years but, as an experienced and ‘empowered’ patient, has reached the point where she can stop her treatment

‘From the shocking diagnosis to the symptom diary: this is how I managed to get the illness under control’

Patients are expected to play an active role in their care pathway and in hospital and institutional working groups, but they need training and a sense of physical and mental balance

The patient at the centre of decision-making and the aim of personalised treatment

The key issues: patients’ ability to understand, monitor and manage their condition, whilst also recognising the impact it continues to have on their daily lives.

Patient involvement in care remains an ongoing challenge

By analysing the activity of 50 genes present in blood cells, scientists have been able to distinguish, with a certain degree of accuracy and good predictive power, which patients are likely to remain in remission

A genetic test will help determine who can stop treatment

Efficacia delle cure e qualità di vita: nuove prospettive

Treatment efficacy and quality of life: new perspectives

Archivio